About
Antibodies, Fusion Proteins
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodySan Diego & Southern California
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
6
As Collaborator
1
Total Enrollment
1,468
By Phase
PHASE2: 2PHASE2/PHASE3: 1PHASE1/PHASE2: 1PHASE1: 3
By Status
RECRUITING: 5COMPLETED: 1TERMINATED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06353997Collaborator
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
PHASE2Recruiting
12 participants
Started: Sep 5, 2024 · Completed: Jun 30, 2029
NCT06295731Lead Sponsor
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
PHASE2/PHASE3Recruiting
410 participants
Started: May 14, 2024 · Completed: May 31, 2029
NCT04950075Lead Sponsor
Study of INBRX-109 in Conventional Chondrosarcoma
PHASE2Recruiting
201 participants
Started: Sep 23, 2021 · Completed: Dec 31, 2026
NCT04198766Lead Sponsor
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
PHASE1/PHASE2Recruiting
333 participants
Started: Dec 10, 2019 · Completed: May 12, 2027
NCT03815396Lead Sponsor
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
PHASE1Completed
31 participants
Started: Jul 19, 2019 · Completed: Aug 18, 2022
Locations (1)
Headquarters
La Jolla, CA, United States
Map
Loading map...